Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Borderi

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Le Infezioni in Medicina|November 28, 2006
[Multifactorial relations between HIV, HAART and bone metabolism]Marco Borderi
Acta Bio-Medica : Atenei Parmensis|September 18, 2012
Biases in bone metabolism studiesMarco Borderi, Pierluigi Viale
Le Infezioni in Medicina|March 16, 2020
HIV policy in Italy and recommendations across the HIV care continuumMassimo Galli, Marco Borderi, Pierluigi Viale
The New Microbiologica|September 7, 2007
Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical managementIsabella Bon, Federica Alessandrini, Marco Borderi, et al.
The New Microbiologica|July 16, 2008
Bone alterations during HIV infectionElisa De Crignis, Laura Cimatti, Marco Borderi, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 29, 2009
HIV-1 infection of a nurse from a newborn with an unknown HIV infection: a case reportDavide Gibellini, Marco Borderi, Isabella Bon, et al.
Infectious Diseases (London, England)|December 27, 2019
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-upLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
The New Microbiologica|July 8, 2009
Paradoxical immune reconstitution inflammatory syndrome associated with previous Cryptococcus neoformans infection in an HIV-positive patient requiring neurosurgical interventionCarlo Biagetti, Monica Nicola, Marco Borderi, et al.
Antiviral Therapy|September 26, 2015
Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot studyLeonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, et al.
AIDS Research and Human Retroviruses|September 16, 2020
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/EmtricitabineLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Le Infezioni in Medicina|November 28, 2006
[Multifactorial relations between HIV, HAART and bone metabolism]Marco Borderi
Acta Bio-Medica : Atenei Parmensis|September 18, 2012
Biases in bone metabolism studiesMarco Borderi, Pierluigi Viale
Le Infezioni in Medicina|March 16, 2020
HIV policy in Italy and recommendations across the HIV care continuumMassimo Galli, Marco Borderi, Pierluigi Viale
The New Microbiologica|September 7, 2007
Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical managementIsabella Bon, Federica Alessandrini, Marco Borderi, et al.
The New Microbiologica|July 16, 2008
Bone alterations during HIV infectionElisa De Crignis, Laura Cimatti, Marco Borderi, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 29, 2009
HIV-1 infection of a nurse from a newborn with an unknown HIV infection: a case reportDavide Gibellini, Marco Borderi, Isabella Bon, et al.
Infectious Diseases (London, England)|December 27, 2019
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-upLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
The New Microbiologica|July 8, 2009
Paradoxical immune reconstitution inflammatory syndrome associated with previous Cryptococcus neoformans infection in an HIV-positive patient requiring neurosurgical interventionCarlo Biagetti, Monica Nicola, Marco Borderi, et al.
Antiviral Therapy|September 26, 2015
Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot studyLeonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, et al.
AIDS Research and Human Retroviruses|September 16, 2020
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/EmtricitabineLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
Pageof 7